Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

Table 2 Clinical characteristics of bone marrow metastatic neuroblastoma patients according to MYCN and 11q23 statuses

Variable	MYCN status [cases (%)]		P value*	11q23 status [cases (%)]		P value*
Variable	Amplified	Normal	P value*	Deleted	Normal	P value*
Total	12	89		40	61
Sex
Male	7 (58.3)	50 (56.2)	0.536	24 (60.0)	33 (54.1)	0.682
Female	5 (41.7)	39 (43.8)		16 (40.0)	28 (45.9)
Age (months)
< 18	4 (33.3)	12 (13.5)	0.095	2 (5.0)	14 (23.0)	0.024
≥ 18	8 (66.7)	77 (86.5)		38 (95.0)	47 (77.0)
Primary tumor site
Abdomen	12 (100.0)	76 (85.4)	0.436	33 (82.5)	55 (90.2)	0.339
Thorax	0 (0)	12 (13.5)		6 (15.0)	6 (9.8)
Neck	0 (0)	1 (1.1)		1 (2.5)	0 (0)
LDH (IU/L)
< 1500	1 (8.3)	78 (87.6)	<0.001	32 (80.0)	47 (77.0)	0.808
≥ 1500	11 (91.7)	11 (12.4)		8 (20.0)	14 (23.0)
NSE (ng/mL)
< 370	1 (8.3)	59 (66.3)	< 0.001	21 (52.5)	39 (63.9)	0.302
≥ 370	11 (91.7)	30 (33.7)		19 (47.5)	22 (36.1)
Event
No	1 (8.3)	48 (53.9)	0.004	16 (40.0)	33 (54.1)	0.118
Yes	11 (91.7)	41 (46.1)		24 (60.0)	28 (45.9)

MYCN the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, LDH lactate dehydrogenase, NSE neuron-specific enolase
* The χ² test was used for statistical analysis

ISSN: 2523-3548